1Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clini- cal trials of treatment for complicated skin and skin-structure in- fections and complicated intra-abdominal infections[J]. Clin Infect Dis,2005,41(Suppl 5) :S315-332.
2PAUL I NE YOONG, RAY MOND SCHUCH, DAN IEL NEL- SON, et al. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic resistance Entercococcus fae- calls and Enterococcus faecium[J]. J Bacteriol, 2004: 4808-4812.
5Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staph- ylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Data- base[J]. Areh Intern Med, 2005,165 : 1756-1761.
8Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-produ- cing Klebsiella pneumonia in Brooklyn, NY: molecular epidemiol- ogy and in vitro activity of polymyxin B and other agents[J]. J Antimicrob Chemother,2005, 56: 128-132.
9Gaynes R, Edwards JR: Overview of nosocomial infections caused by gram-negative bacilli[J]. Clin Infect Dis,2005, 41:848-854.
10Fass RJ, Gregory WW, Damato RF, et al. In vitro activities of cefoperazone and sulbactam singly and in combination against ce- foperazone-resistant members of the family ecterobacteriaeeae and nonfermenters[J]. Antimicrob Agents Chemother, 1990, 34 (11) :2256-2259.
10Cizman M, Srovin T, Pokorn M, et ah Analysis of the causes and consequences of decreased antibiotic consumption over the last 5 years in Slovenia [ J ]. J Antimicrob Chemother, 2005,55 (5) : 758- 763.
9Gilbert D N, Guidos R J, Boucher H W, et al. The 10 × ' 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020[J]. Clin Infect Dis, 2010, 50(8): 1081-1083.
10Wilson Z E, Brimble M A. Molecules derived from the extremes of life[J]. Nat Prod Rep, 2009, 26(1):44-71.
